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Optimal management when unsuspected N2 nodal disease
is identified during thoracotomy for lung cancer:
Cost-effectiveness analysis
Mark K. Ferguson, MD
Objectives: Whether to proceed with lung resection when N2 nodal disease is
identified at the time of thoracotomy for lung cancer is controversial. A decision
analysis model was developed to address this question.
Methods: A meta-analysis was performed on data from reports published between
1990 and 2002 evaluating survival for (1) patients who were treated by initial
resection for clinically unsuspected N2 nodal disease (initial resection) and (2)
survival for patients undergoing resection after neoadjuvant therapy for N2 nodal
disease (no initial resection). Hospital cost data for surgery were derived from our
institution, and cost data for chemotherapy and radiation therapy were obtained
from current literature. A decision model was developed to compare initial resection
to no initial resection from the perspective of the medical center using survival,
quality-adjusted life years survival, and cost-effectiveness as outcomes.
Results: The no initial resection option provided better median survival (2.1 versus
1.7 years), quality-adjusted life years (1.8 versus 1.3), and cost-effectiveness, with
an incremental cost-effectiveness ratio of $17,119/quality-adjusted life year. Out-
comes were influenced by survival estimates for each treatment option.
Conclusions: When N2 nodal disease is discovered during thoracotomy, the ap-
proach of delaying resection until after neoadjuvant therapy provides the best
survival and is more cost-effective. This is likely due to the beneficial effects of
neoadjuvant therapy and the exclusion of patients with more aggressive disease
from the surgical candidate pool.
The appropriate management of patients with non–small cell lungcancer (NSCLC) metastatic to N2 lymph nodes is controversial.Results of 2 randomized trials indicate that neoadjuvant therapyfollowed by resection in selected patients improves long-term anddisease-free survival compared with resection alone.1,2 These find-ings suggest that in patients in whom there is a suspicion of N2 nodal
disease based on clinical findings, an evaluation such as mediastinoscopy, thora-
coscopy, or positron emission tomography (PET) is appropriate to document N2
nodal status. If N2 nodal disease is identified prior to thoracotomy, such patients
should undergo neoadjuvant therapy possibly followed by resection.
A more difficult problem is appropriate management of patients in whom N2
nodal disease is not suspected prior to thoracotomy but is identified intraoperatively,
prior to formal lung resection. Options for management include proceeding with
lung resection or aborting the resection to permit neoadjuvant therapy possibly
followed by subsequent resection. Most surgeons favor proceeding with lung
resection in this situation, theorizing that the patient has already been exposed to the
major risks associated with surgical care of lung cancer. However, there are no trials
that have compared outcomes of these 2 choices.
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Analyzing the potential benefits of competing choices for
surgical therapy in the absence of reliable information re-
garding the relative utility of each option is difficult. Deci-
sion analysis techniques have recently been used to explore
such situations, particularly those in which the performance
of randomized clinical trials aimed at definitively answering
such questions is impractical. A decision analysis model
was developed to explore whether initial resection or neo-
adjuvant therapy followed by resection is most effective in
patients with clinically unsuspected N2 nodal disease dis-
covered at the time of thoracotomy for NSCLC.
Methods
A Medline search of reports published in English from 1990 to
2002 using the combined search criteria [“lung resection” and
“lung neoplasm”] and [“stage III” or “stage IIIa” or “mediastinal
adenopathy” or “N2”] using the current staging system was per-
formed and yielded 457 articles.3 One-hundred thirteen abstracts
were reviewed and a related article search was performed on
appropriate abstracts. Articles that were selected satisfied these
criteria: at least 25 patients in each surgical candidate group;
median survival was stated or calculable for N2 patients; and
operative mortality was reported or calculable for N2 patients.
Data related to malignancies other than NSCLC and information
for patients with other than stage IIIa disease were discarded. Data
were abstracted for patients who underwent neoadjuvant chemo-
therapy or chemoradiotherapy as part of prospective trials for
clinically or histologically documented N2 disease, whereas data
were abstracted for patients who underwent initial resection and
who had no clinical evidence for pathologic N2 disease.
Meta-analyses of the resultant data were performed including
calculation of weighted mean survival for the surgical groups.
Estimates for other parameters were derived from studies4-49 pub-
lished during the same time interval (Table 1). Quality-adjusted
life years (QALY) was calculated by multiplying median survival
(expressed in years) by a quality-of-life utility scale that was
estimated from recent reports and in which death had a value of 0
and full health had a value of 1 (Table 1). Cost information for
surgery was obtained from data collected on 100 patients who
underwent thoracotomy for lung resection at the University of
Chicago from 1998 to 2001 under a protocol that was approved by
the Institutional Review Board and for which specific patient
consent was not required. Cost information for chemotherapy and
radiation therapy was obtained from current literature (Table 1). In
all cases only direct cost information was used, and all costs were
normalized to 2002 US dollars based on the Consumer Price Index.
Ranges for variables were calculated based on 95% confidence
intervals when available or were estimated when necessary.
A decision analysis model was created using a dichotomous
choice between resection and no initial resection to explore the 2
available options for managing patients with NSCLC accompanied
by clinically unsuspected N2 nodal disease discovered at the time
of thoracotomy (Figure 1). It was assumed that patients undergoing
neoadjuvant therapy received 2 cycles of chemotherapy with 2
agents and 50-Gy radiation therapy. Periods of decreased quality
of life were assumed to be 0.1 years for postoperative patients who
were to receive neoadjuvant or adjuvant therapy, 0.2 years for
postoperative patients who did not receive neoadjuvant or adjuvant
therapy, and 0.2 years for administration of neoadjuvant or adju-
vant therapy. No adjustment was made for quality of life at end of
life. Outcomes (rewards) were analyzed from the perspective of
TABLE 1. Values for variables used in decision model
Variable Value Range References
Initial resection group
Operative mortality 0.03 0.01-0.05 4-13
Likelihood of postoperative RT 0.25 0.15-0.35 4-13
Likelihood of postoperative CRT 0.5 0.4-0.6 4-13
Survival—resection only (years) 1.8 1.2-2.4 4-13
Survival—resection and adjuvant therapy (years) 1.8 1.2-2.4 14-16
No initial resection group
Operative mortality for exploration 0.005 0.002-0.01 17
Operative mortality for subsequent resection 0.05 0.03-0.07 13,18-35
Likelihood of subsequent resection 0.7 0.5-0.9 13,18-35
Survival—neoadjuvant therapy and resection (years) 2.6 2.0-3.2 1,2,13,18-23,26-35
Survival—neoadjuvant therapy only (years) 1.0 0.8-1.2 2,22,29,35-37
Other global variables
Cost RT ($) 2744 2000-3500 38,39
Cost CRT ($) 6932 5223-8652 38-45
Cost resection ($) 14,214 13,178-14,800 Study data
Cost surgical exploration ($) 8900 7100-10,700 Study data
Cost operative mortality ($) 36,787 25,000-48,574 Study data
Quality-of-life during postoperative recovery 0.75 0.6-0.9 46,47
Quality-of-life during RT 0.7 0.5-0.9 38,39
Quality-of-life during neoadjuvant or adjuvant CRT 0.65 0.5-0.8 38-45
Quality-of-life after all therapy completed 0.85 0.75-0.95 46-49
RT, Radiation therapy; CRT, chemoradiotherapy.
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the medical center and included median survival, QALY, and
cost-effectiveness. The incremental cost-effectiveness ratio
(ICER) was determined and was compared with a willingness-to-
pay threshold of $50,000/QALY. One-way sensitivity analyses
were performed on all variables, and 2-way sensitivity analyses
were performed on selected variables. Statistical analyses were
performed with Minitab 12.1 (Minitab, Inc, State College, Pa) and
Data Pro (release 7.0; TreeAge Software, Inc, Williamstown,
Mass) was used for all decision analyses.
Results
Data were obtained on 1046 patients without clinical evi-
dence of N2 nodal disease who underwent resection without
neoadjuvant therapy and on 775 patients who were found to
have N2 disease prior to resection and who underwent
neoadjuvant chemotherapy or chemoradiotherapy alone
(175 patients) or followed by resection (600 patients). Using
median survival as the reward, the decision model favored
no initial resection (2.1 years versus 1.7 years). Using
QALY as the reward, the decision model favored no initial
resection (1.8 QALY versus 1.3 QALY). When cost-effec-
tiveness was analyzed, the no initial resection option was
more costly but also provided greater QALY ($27,000/1.8
QALY versus $19,000/1.3 QALY); neither management
option was dominant. The ICER was $17,119/QALY,
which is well below the standard willingness-to-pay thresh-
old of $50,000/QALY (Table 2). Based on 1-way sensitivity
analyses, the model was influenced by survival estimates,
both for the initial resection followed by adjuvant therapy
group (threshold 2.28 QALY; Figure 2) and for the no initial
resection group (threshold 2.07 QALY; Figure 3). A 2-way
sensitivity analysis for these variables demonstrated the no
initial resection option to provide greater value (Figure 4).
Discussion
Optimal management of patients with NSCLC who have
clinically negative N2 nodes but who are discovered to have
N2 nodal disease at the time of thoracotomy is controver-
sial. Most surgeons recommend proceeding with resection
in otherwise healthy patients who have relatively favorable
findings, such as a single N2 nodal level involved, absence
of capsular invasion, and a T1 or T2 primary tumor. It has
been suggested that resection is justified in such patients,
“who have already necessarily incurred the morbidity and
mortality of thoracotomy.”8 However, even though selected
patients appear to have favorable long-term survival, the
overall outcomes after surgery for N2 nodal disease are far
from satisfactory. In addition, important morbidity after
exploratory thoracotomy without resection is rare, mortality
is negligible, and long-term outcomes are not appreciably
affected.17,50
No information from randomized trials is available re-
garding the respective outcomes for these choices, and such
a trial is unlikely to be performed. Nevertheless, the man-
agement question is an important one, if only because the
incidence of clinically unsuspected N2 nodal involvement is
as high as 15% to 25% in patients undergoing thoracotomy
for resection.8,51 Favorable survival may be related to a
number of anatomic factors, such as the specific nodal
stations involved, the number of involved nodes, and
whether the disease is gross or microscopic. However, it is
likely that the tumor biology in each patient is the most
important determinant of long-term outcome. Delaying re-
section to enable assessment of tumor biology, in part by
evaluating the response of the tumor to neoadjuvant ther-
apy, may help select patients in whom resection is most
appropriate.
Medical applications of decision analysis techniques
were originally developed in the 1970s to provide insight
into the management of individual patients. They have
recently been found useful for developing policies about
groups of patients by providing information on which of 2
or more management strategies has the most value.52 These
Figure 1. Decision model for assessing optimal therapy for non–small cell lung cancer with N2 nodal disease
discovered at the time of thoracotomy. The square represents the decision node, the circles are chance nodes, and
the triangles are terminal nodes. RT, radiotherapy; CRT, chemoradiotherapy.
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“thought experiments” may be based on real data or may
rely entirely on hypothetical values gleaned from clinical
experience. In either situation, these exercises are useful in
situations in which real experiments involving patients are
impractical or impossible to conduct.
The reports selected from which data were abstracted for
inclusion in this decision model favored the choice of initial
resection. Patients who underwent initial resection had no
clinical evidence for N2 disease prior to thoracotomy. In
contrast, patients who had no initial resection often had
clinical evidence for N2 nodal disease, a characteristic that
has been associated with poor long-term survival. Similarly,
operative mortality selected for the initial resection arm of
the decision model was lower than that selected for the no
initial resection arm, although favorable postoperative out-
comes have been reported for patients after neoadjuvant
therapy. Despite the fact that the patient characteristics in
the sampled reports appeared to favor the choice of initial
resection, the decision analysis favored the no initial resec-
tion arm for each of the outcomes analyzed.
The primary reason why postponed resection had an
advantage in this model was the survival advantage evident
in the literature for patients who underwent neoadjuvant
therapy compared with patients who underwent initial re-
section for N2 nodal disease. It is possible that the differ-
ence in calculated survival is spurious. Patients treated with
neoadjuvant therapy were usually part of prospective trials
and were subjected to more rigorous preoperative staging
than patients who underwent initial resection. This helped
ensure that the patients receiving neoadjuvant therapy did
not have N3 disease, which remained a possibility in some
patients who had initial resection. However, a survival
advantage has been demonstrated in randomized studies for
patients with N2 nodal disease who received neodadjuvant
therapy followed by resection compared with resection
alone, suggesting that a real benefit is conferred by neoad-










Initial resection 19,000 1.34 $14,193/QALY
Neoadjuvant therapy followed
by resection
27,000 8,000 1.80 0.45 $14,933/QALY $17,119/QALY
ICER, Incremental cost-effectiveness ratio; QALY, quality-adjusted life years.
Figure 2. One-way sensitivity analysis for survival after initial
surgery followed by adjuvant therapy. The possible outcomes are
compared with the incremental cost/QALY of the no initial resec-
tion option. The value for survival above which the incremental
cost/QALY of the no initial resection option exceeds the willing-
ness-to-pay threshold of $50,000/QALY (horizontal dotted line) is
2.28 QALY (vertical dotted line).
Figure 3. One-way sensitivity analysis for survival after no initial
resection followed by neoadjuvant therapy and resection. The
possible outcomes are compared with the incremental cost/QALY
of the no initial resection option. The value for survival below
which the incremental cost/QALY of the no initial resection
option exceeds the willingness-to-pay threshold of $50,000/QALY
(horizontal dotted line) is 2.07 QALY (vertical dotted line).
General Thoracic Surgery Ferguson
1938 The Journal of Thoracic and Cardiovascular Surgery ● December 2003
G
TS
juvant therapy.1,2 In contrast, most published evidence sug-
gests that if multimodality therapy is to be given, it should
be done as neoadjuvant therapy followed by surgery.14-16
Many approaches to modeling staging and therapy for
regionally advanced lung cancer are possible. For example,
the routine use of mediastinoscopy may reduce the percent-
age of patients discovered to have N2 disease at the time of
thoracotomy but would not appreciably change the manage-
ment options at the time of thoracotomy. In addition, end-
of-life issues are not addressed. These include costs and
quality of life (QOL) associated with death owing to recur-
rent disease and those associated with death resulting from
intercurrent disease. No reliable data regarding these issues
are available. Finally, the current model does not include an
option for postoperative adjuvant chemotherapy, a treat-
ment option that is offered to some patients who complete
neoadjuvant therapy but have residual nodal disease at the
time of resection. Recent information suggests the possibil-
ity that such therapy may improve long-term survival by a
few percentage points.53 Inclusion of such options would
not alter the conclusions of this study because of the large
gap between the ICER and the willingness-to-pay threshold.
Estimations of QOL formed an important part of the
calculation of incremental cost-effectiveness ratio, upon
which the conclusions of this study are based. Both the
duration of reduced QOL associated with therapy and the
amount of reduction of QOL are insufficiently studied.
More is known about the effects of chemotherapy than is
known about the effects of radiotherapy or surgery. Fortu-
nately, the results reported for both radiotherapy and for
surgery are relatively consistent regarding the amount of
reduction in QOL; less is known about the duration of QOL
reduction for these treatment modalities.
The ranges of values for QOL were purposely set rather
wide to account for the fact that the QOL values were
possibly not as reliable as values for other variables. How-
ever, given the large discrepancy in long-term survival, the
relatively small duration of reduced QOL, and the similar
overall QOL for all 3 outcome groups, it would take a
considerable and isolated reduction in QOL for the no initial
resection group to result in a change in the conclusions of
this study.
The results demonstrate that rather than resecting pa-
tients who are identified as having N2 nodal disease at the
time of initial exploratory thoracotomy, the option of post-
poning resection and referring patients for neoadjuvant ther-
apy was preferred in this model. This was likely due to the
beneficial effects of neoadjuvant therapy and the exclusion
of patients with more aggressive disease from the surgical
candidate pool. This permitted subsequent resection for
selected patients, presumably those who had more favorable
tumor biology, and provided the best outcomes in terms of
survival and QALY. Most importantly, the cost-effective-
ness analysis yielded an ICER of only $17,119/QALY, a
value that is well within commonly accepted willingness-
to-pay thresholds.54
The findings of this study will hopefully stimulate phy-
sicians who care for lung cancer patients to consider the
potential benefits of preoperative and intraoperative staging
prior to proceeding with lung resection. Ongoing efforts
exploring the relative merits of PET, mediastinoscopy, and
endoscopic ultrasonography may help clarify preoperative
staging options. Although several reports demonstrate a
survival advantage for patients with limited N2 nodal in-
volvement, accurate determination of the extent of N2 nodal
involvement is often not possible during intraoperative stag-
ing due to sampling errors and the limitations of frozen
section techniques. As a result, differentiating between fa-
vorable and unfavorable N2 disease intraoperatively may
not be possible. The results of the present study suggest that
when clinically unsuspected N2 disease is discovered intra-
operatively, delaying resection until after completion of
neoadjuvant therapy is beneficial.
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Discussion
Dr Douglas J. Mathisen (Boston, Mass). I think you have
brought to our attention an important point, albeit a very small
point. I think in your article the emphasis on staging can’t be
stressed enough, and if one does thorough mediastinal staging, this
problem ought to be relatively uncommon.
I don’t think anybody would argue the notion that if N2 disease
is discovered at mediastinoscopy that neoadjuvant therapy clearly
has a role to play. I think it’s still somewhat of an open question,
however. We are all familiar with the 2 series that you presented;
they are oftentimes quoted. They are small series with a mixture of
patients in them, and therefore the conclusions that they reach, at
least the magnitude of the conclusions, I think, can be called into
question. The conclusion that you have come to is not necessarily
intuitively obvious to the surgeon, and because of that, it causes
me to question some of the assumptions upon which this statistical
analysis is based, and I would like your thoughts about those.
First and foremost, in the article you mentioned that some of
those patients who have neoadjuvant therapy and then surgery
included patients who had clinical N2 disease. Clearly that is a
factor we all are aware may be spurious, and some of those that are
thought to be clinically positive may turn out to be negative.
Secondly, at least if I’ve read the article correctly, of those patients
who had surgery and then adjuvant therapy, only 75% of them
went on to adjuvant therapy, and of the ones who went on to
adjuvant therapy, only 50% had chemoradiotherapy. Would it not
have been better to examine only those patients who had surgery
plus adjuvant therapy? And furthermore, in the group that had
neoadjuvant therapy, again, if I read the article correctly, only 70%
had surgery. So shouldn’t we have focused on the ones who had
neoadjuvant therapy plus surgery? The other assumption that you
state upon which many of the conclusions are based has to do with
the survival data. As we saw in this slide and as is pointed out in
the article, the survival for surgery, plus surgery, plus adjuvant
therapy is the same, 1.8 years. Yesterday we heard a presentation
on surgery plus adjuvant therapy for single nodes involved where
the median survival was 3 years. Based on that kind of a report,
does it change your interpretation or at least your sense of the
interpretation of this data?
Dr Ferguson (Chicago, Ill). First of all, I would like to com-
ment on the relative importance of this. I agree that clinical staging
and pathologic staging, ideally before you get to the thoracotomy,
is important. The data I used were from numerous studies that
demonstrated no clinical evidence for N2, and in that general type
of clinical practice there is about a 15% incidence of undetected
N2 disease. That translates in the United States to at least several
thousand people annually.
All of the values that I used to enter into the tree are open for
discussion. I’m not trying to mathematically prove anything. In-
stead, what’s been done is a thought experiment. And if others
have a different concept about which values are most appropriate
to enter in, then they can plug those in and see what the outcomes
are. These are just the best estimates that I can come up with from
the data and from the literature.
Patients who had neoadjuvant therapy followed by surgery by
and large universally had pathologic documentation of N2 disease
prior to entering into that treatment program, and so I don’t think
that there is a potential survival advantage that’s very significant in
those patients because of clinical evidence for N2 that was not
actually pathological N2 disease. You mentioned the possibility of
using just patients who receive chemotherapy and radiation ther-
apy in the initial resection group, and, in fact, according to most
studies, that would not have affected long-term survival but would
have increased the cost of therapy in this group. Thus, the outcome
would have swayed even further toward no initial resection. With
regards to Steve Keller’s presentation yesterday regarding survival
in single-station N2 disease, if I’m not mistaken, that graph rep-
resented combined N1 and N2 disease displaying 3-year survival.
Dr Mathisen. Well, what I remember from it, and it’s not
worth debating, was that the survival for N2 was 36 months. The
survival for N1 was close to 60 months.
I have 2 final points. One has to do with the mortality: in the
neoadjuvant therapy did it include mortality from the treatment? In
other words, was all treatment-related mortality, neoadjuvant ther-
apy plus surgery, included in the figure that came out to be 5%?
Obviously a slight change in mortality for the 2 groups might
influence the ultimate analysis.
Dr Ferguson. Two mortality rates were quoted, one for the
initial exploratory operation without resection. The second mor-
tality rate was quoted for patients who had completed neoadjuvant
therapy followed by resection. There’s a group of patients who did
not undergo resection. Their mortality that was associated with the
neoadjuvant therapy is included in that nonresection group and
their resultant poorer survival.
Dr Mathisen. Finally, having looked at all of this data that
you’ve collected, can you give us some perspective of the issue of
single nodal station versus multiple nodal stations for the 2 groups
that you looked at?
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Dr Ferguson. Well, I have a personal reflection on it, but I
don’t have any data that I could use to discuss your question. My
sense is that I think we all agree that single-station N2 nodal
disease, particularly isolated stations, like level 5, confer much
better long-term prognosis, but the ability to confirm the existence
of isolated single-station disease, particularly without extracapsu-
lar spread, is very limited, particularly at the time of exploratory
thoracotomy.
Dr Mathisen. And the final question, if tomorrow you had a
patient in whom you did a mediastinoscopy and it was negative,
and you explored them; in the course of your routine you did a
mediastinal node dissection that you had sent to the pathologist
for review and they found a node positive in that patient, prior
to going forward, what would you do with that particular
patient?
Dr Ferguson. That’s when I stop.
Dr Mathisen. Thank you very much.
Dr Frank C. Detterbeck (Chapel Hill, NC). Mark, I also
remain a bit skeptical. You assumed that in all the patients who
underwent thoracotomy and were found to have a positive node
and then closed would actually get neoadjuvant chemotherapy. We
know from the experience with giving adjuvant chemotherapy
after a resection that we very consistently have a hard time actually
delivering that treatment. There are many patients who are non-
compliant, drop out, and so forth. There is no published data that
actually looks at whether can we deliver neoadjuvant chemoradio-
therapy after an exploratory thoracotomy. However, I’m skeptical
that you can do so in all of the patients, and I think that would color
your conclusions.
Dr Ferguson. The point is well taken. It reflects a little bit
about the initial quote that I presented and that the morbidity and
mortality of the thoracotomy has already been incurred, with
which I disagree. The morbidity and mortality should be substan-
tially less. And I think the likelihood of those patients going to
neoadjuvant chemotherapy should be substantially higher than the
percentage of patients who ultimately get adjuvant postoperative
therapy after a formal lung resection. But that perspective was not
entered into the model, you’re correct.
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